Unloxcyt Shines Bright with 50% Response in Skin Cancer Battle

Sun Pharma's Unloxcyt is making waves at the ASCO Annual Meeting in Chicago! With a fantastic 50% response rate in skin cancer patients, this drug is proving it’s a game-changer. After 31 months, the results are still looking great, and the side effects? Totally manageable! It’s a bright spot in the fight against skin cancer.